Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN.
Division of Cardiology, Department of Medicine, West Virginia University, Morgantown.
Mayo Clin Proc. 2020 May;95(5):858-866. doi: 10.1016/j.mayocp.2019.08.023. Epub 2020 Jan 3.
To assess contemporary trends in the incidence, characteristics, and outcomes of hospital admissions for infective endocarditis (IE) in the United States.
Patients ≥18 years admitted with IE between January 1, 2003, and December 31, 2016, were identified in the National Inpatient Sample. We assessed the annual incidence, clinical characteristics, morbidity, mortality, and cost of IE-related hospitalizations.
The incidence of IE-related hospitalizations increased from 34,488 (15.9; 95% confidence interval [CI], 15.73, 16.06) per 100,000 adults) in 2003 to 54,405 (21.8; 95% CI, 21.60-21.97) per 100,000 adults) in 2016 (P<.001). The prevalence of patients below 30 years of age, and those who inject drugs, increased from 7.3% to 14.5% and from 4.8% to 15.1%, respectively (P<.001). The annual volume of valve surgery for IE increased from 4049 in 2003 to 6460 in 2016 (P<.001), but the ratio of valve surgery to IE-hospitalizations did not decrease (11.7% in 2003; 11.8% in 2016). There was also a temporal increase in risk-adjusted rates of stroke (8.0% to 13.2%), septic shock (5.4% to 16.3%), and mechanical ventilation (7.7% to 16.5%; P<.001). However, risk-adjusted mortality decreased from 14.4% to 9.8% (P<.001). Median length-of-stay and mean inflation-adjusted cost decreased from 11 to 10 days and from $45,810±$61,787 to $43,020±$55,244, respectively, (P<.001). Nonetheless, the expenditure on IE hospitalizations increased ($1.58 billion in 2003 to $2.34 billion in 2016; P<.001).
There is a substantial recent rise in endocarditis hospitalizations in the United States. Although the adjusted in-hospital mortality of endocarditis and the cost of admission decreased over time, the overall expenditure on in-hospital care for endocarditis increased.
评估美国感染性心内膜炎(IE)住院患者发病率、特征和结局的当代趋势。
我们在国家住院患者样本中确定了 2003 年 1 月 1 日至 2016 年 12 月 31 日期间年龄≥18 岁、因 IE 入院的患者。我们评估了 IE 相关住院治疗的发病率、临床特征、发病率、死亡率和费用。
IE 相关住院患者的发病率从 2003 年的 34488(15.9;95%置信区间[CI],15.73,16.06)/100000 名成年人上升至 2016 年的 54405(21.8;95%CI,21.60-21.97)/100000 名成年人(P<.001)。年龄在 30 岁以下的患者和吸毒者的比例从 7.3%上升至 14.5%和从 4.8%上升至 15.1%(P<.001)。IE 瓣膜手术的年手术量从 2003 年的 4049 例增加至 2016 年的 6460 例(P<.001),但瓣膜手术与 IE 住院治疗的比例并未下降(2003 年为 11.7%;2016 年为 11.8%)。此外,风险调整后的中风(8.0%至 13.2%)、感染性休克(5.4%至 16.3%)和机械通气(7.7%至 16.5%)的风险调整率也有所增加(P<.001)。然而,风险调整后的死亡率从 14.4%下降至 9.8%(P<.001)。中位住院时间和平均通胀调整后的费用分别从 11 天降至 10 天,从 45810±61787 美元降至 43020±55244 美元(P<.001)。尽管如此,IE 住院治疗的支出(2003 年为 15.8 亿美元,2016 年为 23.4 亿美元)增加了(P<.001)。
美国的感染性心内膜炎住院患者人数近期大幅上升。尽管随着时间的推移,IE 的院内死亡率和住院费用有所下降,但 IE 住院治疗的总支出却有所增加。